Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AK119 + Cadonilimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AK119 | AK 119|AK-119|Dresbuxelimab | CD73 Antibody 12 | AK119 is a monoclonal antibody targeting CD73, which may lead to decreased adenosine via inhibition of the conversion of adenosine monophosphate (AMP) to adenosine, potentially resulting in anti-tumor activity (J Clin Oncol 2021 39:15_suppl, TPS2675). | |
Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 32 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04572152 | Phase I | AK119 + Cadonilimab | A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors | Unknown status | AUS | 0 |